Navigation Links
Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
Date:11/5/2007

CHARLOTTE, N.C., Nov. 5 /PRNewswire-FirstCall/ -- MedCath Corporation (Nasdaq: MDTH) announced today that Arizona Heart Hospital, one of the 11 hospitals in which MedCath owns an interest, has entered into a settlement with the United States Department of Justice (the DOJ) and the United States Attorneys' Office in Phoenix under the federal Civil False Claims Act.

The settlement concerns Medicare claims submitted between June 1998 and October 2002 for physician services involving the implantation of certain endoluminal graft devices (utilized to treat aneurysms) that had not received final marketing approval from the Food and Drug Administration, and allegedly were either implanted without an approved investigational device exception (IDE) or were implanted outside of the approved IDE protocol. The DOJ's allegations related solely to whether the procedures were properly reimbursable by Medicare; quality of patient care was not at issue.

The parties reached a settlement of the allegations to avoid the delay, uncertainty, inconvenience, and expense of protracted litigation. Further, the hospital denies engagement in any wrongdoing or illegal conduct, and the settlement agreement does not contain any admission of liability. As previously disclosed in MedCath's filings with the Securities and Exchange Commission, the hospital will pay approximately $5.8 million to settle and obtain a release from any civil or administrative monetary claims related to the DOJ's investigation. Additionally, the hospital has entered into a five- year corporate integrity agreement with the Office of the Inspector General of the Department of Health and Human Services under which the hospital will continue to maintain its existing corporate compliance program and which relates to clinical trials conducted at the hospital.

MedCath Corporation, headquartered in Charlotte, N.C., is a healthcare provider focused on high acuity services with the diagnosis and treatment of cardiovascular disease being a primary service offering. MedCath owns interests in and operates eleven hospitals with a total of 667 licensed beds, located in Arizona, Arkansas, California, Louisiana, New Mexico, Ohio, South Dakota, and Texas. In addition, MedCath and its subsidiary MedCath Partners manage the cardiovascular program at various hospitals and provide services in diagnostic and therapeutic facilities in various states.


'/>"/>
SOURCE MedCath Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
2. Many Heart Attack Patients Dont Get Best Emergency Treatment
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
9. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
10. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
11. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July 21, 2017 ... ) announced today that it will report its second ... Thursday, July 27, 2017. ... July 27, 2017, at 9:00 a.m. Eastern Time.  The ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will be ...
Breaking Medicine Technology:
(Date:7/26/2017)... , ... July 26, 2017 , ... Team Type 1 ... to medicine for everyone affected by diabetes, is excited to announce the 106 college ... Ambassador Program. , Established in 2005, the Team Type 1 Foundation has bestowed ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... dogs and cats has opened in Jupiter. The state of the art ... and class leading treatments with a goal of providing heart patients longer lives. ...
(Date:7/26/2017)... ... 2017 , ... Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) ... development of pharmaceutical and consumer products, announces the operational numbers of its wholly-owned ... International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues of ...
(Date:7/26/2017)... ... 2017 , ... Wendy M. Musielak, a partner at the Andrew Cores Family Law ... Association’s third Vice President earlier this year. She will serve the membership in this capacity ... President, in accordance with the organization’s by-laws. , Musielak joined the Andrew ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or ... ways to improve asthma control in the population are not well described. In a ... Practice), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), ...
Breaking Medicine News(10 mins):